Plasma Biomarker Profiles for Premature and Nonpremature Coronary Heart Disease in Women

Sagar B Dugani,M Vinayaga Moorthy,Olga V Demler,Chunying Li,Paul M Ridker,Robert J Glynn,Samia Mora
DOI: https://doi.org/10.1093/clinchem/hvae007
IF: 12.114
2024-03-13
Clinical Chemistry
Abstract:Abstract Background Premature coronary heart disease (CHD) is a major cause of death in women. We aimed to characterize biomarker profiles of women who developed CHD before and after age 65 years. Methods In the Women’s Health Study (median follow-up 21.5 years), women were grouped by age and timing of incident CHD: baseline age <65 years with premature CHD by age 65 years (25 042 women; 447 events) and baseline age ≥65 years with nonpremature CHD (2982 women; 351 events). Associations of 44 baseline plasma biomarkers measured using standard assays and a nuclear magnetic resonance (NMR)-metabolomics assay were analyzed using Cox models adjusted for clinical risk factors. Results Twelve biomarkers showed associations only with premature CHD and included lipoprotein(a), which was associated with premature CHD [adjusted hazard ratio (HR) per SD: 1.29 (95% CI 1.17–1.42)] but not with nonpremature CHD [1.09(0.98–1.22)](Pinteraction = 0.02). NMR-measured lipoprotein insulin resistance was associated with the highest risk of premature CHD [1.92 (1.52–2.42)] but was not associated with nonpremature CHD (Pinteraction <0.001). Eleven biomarkers showed stronger associations with premature vs nonpremature CHD, including apolipoprotein B. Nine NMR biomarkers showed no association with premature or nonpremature CHD, whereas 12 biomarkers showed similar significant associations with premature and nonpremature CHD, respectively, including low-density lipoprotein (LDL) cholesterol [1.30(1.20–1.45) and 1.22(1.10–1.35)] and C-reactive protein [1.34(1.19–1.50) and 1.25(1.08–1.44)]. Conclusions In women, a profile of 12 biomarkers was selectively associated with premature CHD, driven by lipoprotein(a) and insulin-resistant atherogenic dyslipoproteinemia. This has implications for the development of biomarker panels to screen for premature CHD.
medical laboratory technology
What problem does this paper attempt to address?